Orient EuroPharma Co., Ltd. Stock price

Equities

4120

TW0004120001

Food Processing

End-of-day quote Taipei Exchange 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
43.4 TWD -0.34% Intraday chart for Orient EuroPharma Co., Ltd. +3.09% +11.57%
Sales 2022 4.73B 148M Sales 2023 4.59B 144M Capitalization 3.37B 106M
Net income 2022 -311M -9.73M Net income 2023 144M 4.51M EV / Sales 2022 1.33 x
Net Debt 2022 3.15B 98.68M Net Debt 2023 2.74B 85.74M EV / Sales 2023 1.33 x
P/E ratio 2022
-10.1 x
P/E ratio 2023
23.4 x
Employees -
Yield 2022 *
-
Yield 2023
2.57%
Free-Float 35.17%
More Fundamentals * Assessed data
Dynamic Chart
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Orient EuroPharma Co., Ltd. Appoints Jack Wang as Accounting Officer CI
Orient EuroPharma Co., Ltd. Appoints Jack Wang as Financial Officer CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Orient EuroPharma, OncoVent Sign License Deal MT
OncoVent Enters into a License and Distribution Agreement with Orient EuroPharma for the Immunotherapeutic Candidate Oregovomab CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Orient EuroPharma Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
More news
1 day-0.34%
1 week+3.09%
Current month+7.03%
1 month+6.90%
3 months+11.14%
6 months+1.40%
Current year+11.57%
More quotes
1 week
41.90
Extreme 41.9
43.85
1 month
40.40
Extreme 40.4
43.85
Current year
36.70
Extreme 36.7
43.85
1 year
35.65
Extreme 35.65
48.30
3 years
32.10
Extreme 32.1
48.80
5 years
32.10
Extreme 32.1
65.80
10 years
32.10
Extreme 32.1
104.00
More quotes
Managers TitleAgeSince
Chairman - -
Investor Relations Contact - -
Comptroller/Controller/Auditor - 20-12-31
Members of the board TitleAgeSince
Director/Board Member 64 02-12-31
Chairman - -
Director/Board Member - 22-06-29
More insiders
Date Price Change Volume
24-03-28 43.4 -0.34% 134,214
24-03-27 43.55 +3.32% 138,802
24-03-26 42.15 -0.59% 42,232
24-03-25 42.4 +1.07% 99,915
24-03-22 41.95 -0.12% 111,639

End-of-day quote Taipei Exchange, March 27, 2024

More quotes
Orient Europharma Co., Ltd. is principally engaged in the manufacture and distribution of nutritious healthcare products and medical cosmetic products, as well as western drugs. The Company operates nutritious healthcare products and medical cosmetic products segment, providing infant milk powders, nutritious products and functional healthcare products, as well as dermatological preparations, medical hair care series, organic skin care series and medical make-up products, among others; western drugs segment, providing products for cardiovascular diseases, cancer, blood diseases, diabetes, central nervous system diseases and asthma, among others.
More about the company
  1. Stock
  2. Equities
  3. Stock Orient EuroPharma Co., Ltd. - Taipei Exchange